Consensus Altimmune, Inc.

Stocks

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 23/10/2026 +04			5-day change	1st Jan Change
2.170 ^USD	-2.69%		-8.05%	-39.89%

09-30	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
09-29	Altimmune, Inc. Announces Appointment of Richard Menziuso as Global Controller and Principal Accounting Officer, Effective September 29, 2026	CI

Evolution of the Average Target: Altimmune, Inc.

Evolution of the Target Price: Altimmune, Inc.

Changes in Analyst Recommendations: Altimmune, Inc.

96e65304d5b.ajeDh3TMTYEVULb1DdssLwoQVoWj9SJa-CIlraU9uXM.W37E0kK0B-JiKPWaS6tnSkklMLzgwEEPtRdKmugJiyshfbO_RLp50Thi4w~9049f6dd3356158f4a6dfb543ac1ceda

Analysts' recommendations: Altimmune, Inc.

06-22	Leerink Partners Initiates Altimmune at Outperform With $10 Price Target	MT
04-24	Goldman Sachs Upgrades Altimmune to Neutral From Sell, Adjusts Price Target to $2.50 From $1	MT
03-19	Truist Initiates Altimmune at Buy With $12 Price Target	MT
03-06	B. Riley Adjusts Price Target on Altimmune to $13 From $18, Maintains Buy Rating	MT
01-28	Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target	MT
13/08/25	UBS Adjusts Price Target on Altimmune to $24 From $26, Maintains Buy Rating	MT
13/08/25	B. Riley Adjusts Price Target on Altimmune to $18 From $20, Maintains Buy Rating	MT
28/02/25	William Blair Initiates Altimmune at Market Perform	MT
08/01/25	Stifel Initiates Altimmune at Buy With $18 Price Target	MT
12/11/24	UBS Initiates Altimmune at Buy With $26 Price Target	MT
29/04/24	Altimmune Shares Decline After Guggenheim Downgrade	MT
29/04/24	Guggenheim Downgrades Altimmune to Neutral From Buy	MT
17/01/24	B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating	MT
09/11/23	B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating	MT
14/08/23	HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating	MT
11/08/23	B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating	MT
10/08/23	B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating	MT
22/03/23	Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20	MT
20/01/23	HC Wainwright Reiterates Altimmune at Buy With $50 Price Target	MT
18/01/23	Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating	MT
01/12/22	Goldman Sachs Initiates Altimmune at Buy With $20 Price Target	MT
11/11/22	JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating	MT
28/09/22	Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight	CI
16/09/22	Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating	MT
31/08/22	Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ALTIMMUNE, INC.					+688.53%
	WUXI APPTEC CO., LTD.					+35.78%
	ARGENX SE					+28.93%
	LONZA GROUP AG					+10.89%
	IQVIA HOLDINGS INC.					+8.75%
	BEONE MEDICINES AG					+14.18%
	REVOLUTION MEDICINES, INC.					+37.21%
	CELLTRION, INC.					+37.85%
	WUXI BIOLOGICS (CAYMAN) INC.					+32.7%
	GENMAB A/S					+4.59%
	Average					+89.94%
	Weighted average by Cap.					+24.58%